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| INTRODUC TI ON
Presently, although assisted reproductive technology offers several advances and benefits, it has been unable to resolve the issues arising in women who have lost ovarian function due to different reasons. Chemotherapy and radiotherapy can occasionally induce gonadal disorders and permanent ovarian failure. 1, 2 Chemotherapy has been reported to reduce fertility and cause ovarian dysfunction. [3] [4] [5] In addition, early menopause has been reported to occur, even if the ovarian function is maintained, in patients after the completion of cancer treatment. [5] [6] [7] However, even if the menstrual cycle recovers after chemotherapy in patients with cancer, pregnancy might not be possible due to decreased ovarian function.
Cyclophosphamide (CPA), an alkylating agent that has been used for a long time in chemotherapy, is often used in the treatment of blood diseases and autoimmune diseases and is known to act like a reproductive toxin, as demonstrated in several clinical reports and animal experiments. [8] [9] [10] [11] [12] Therefore, with CPA treatment, various fertility preservation strategies are applied, depending on the risk of gonadal dysfunction, the condition of the patient at the time of preservation of the fertile surnames, and the presence or absence of a partner.
13,14
These strategies include in vitro fertilization (IVF), embryo cryopreservation, ovarian tissue cryopreservation, oocyte freezing, in vitro maturation, and hormonal treatment. Currently, the most effective methods are IVF and embryo or oocyte cryopreservation.
The administration of chemotherapy agents at the ovarian hyperstimulated stage could lead to toxicity to the ovaries. However, until date, investigations on the effects of ovarian stimulation being exposed to cytotoxic substances remain scarce. Recently, a study reported that CPA administration affected the ovarian reserve when ovarian stimulation was conducted prior to the treatment. 15 These results support that ovarian stimulation and IVF-embryo cryopreservation procedures should be performed prior to chemotherapy for the safety of fertility preservation.
Moreover, the vitrification method of unfertilized oocytes
demonstrated improved results and a higher survival rate than those in the conventional slow-freezing methods. One study reviewed more than 936 cases of babies who were born by cryopreserved oocytes and found no apparent increase in the congenital abnormalities in them. 16 Young, unmarried patients who wish to preserve their unfertilized oocytes before or after chemotherapy administration can now cryopreserve their own oocytes for reproductive treatments in the future. The reports on the oocyte conditions during or after cancer drug administration are limited. Therefore, through the present study was investigated the effects of ovarian stimulation on ovarian function following CPA administration. In addition, the ability of oocyte fertilization after CPA administration was investigated in mice.
| MATERIAL S AND ME THODS
Mature ICR strain mice (female mice: aged 8 weeks; male mice: aged 9-12 weeks) were used in this study. All the experiments were approved by the ethics committee within St. Luke's Clinic, Oita, Japan.
The experiments were conducted in two phases.
| Phase 1
To investigate the effects of ovarian stimulation immediately following CPA administration on future ovarian function, the mice were ad- 
| Phase 2
To evaluate the oocyte fertilization efficiency and the influences of 
| Statistical analysis
A chi-square test and t test were performed, with P < .05 considered to be statistically significant.
| RE SULTS

| Phase 1
The number of mice in which the oocytes could be retrieved was compared among different CPA dose injections and found to be significantly decreased with a ≥400 mg/kg CPA dosage (P < .01; Table 1 ). The average number of retrieved oocytes was dramatically decreased when the CPA dosage exceeded 400 mg/kg (P < .01; Figure 1 ). The average number of oocytes that developed to metaphase II (MII) significantly decreased when 400 mg/kg and 800 mg/kg of CPA was administered (P < .01; Figure 2 ). The fertilization rate and embryo development features are shown in Table 2 . Although the fertilization rate decreased with the administration of 400 mg/kg of CPA, the morulation and blastocyst formation rates remained the same as the control group rate.
| Phase 2
After 2 weeks of CPA administration, IVF was performed. The number of mice from which the oocytes could be retrieved significantly decreased to 50%. However, after 1 month, the oocyte retrieval rate increased to 90% (P < .05). The rate of MII oocytes per total cumulus oocytes complex was not significantly different from that of the control group (Table 3) . In IVF, the fertilization rate and the morula and blastocyst formation rates were not different from those of the controls under a similar condition and time period (Table 4) .
| D ISCUSS I ON
The present animal study demonstrated that ovarian stimulation after CPA treatment affected the number of retrieved oocytes. Thus, the production of oocytes was significantly decreased by a higher CPA dose. However, the recovered oocytes developed normally in IVF. Moreover, after 2 weeks of CPA treatment, the fertilization potential of the oocyte remained unchanged despite a significant decrease in the number of mice from which the oocytes could be retrieved. One month after CPA administration, the number of retrieved oocytes and the fertilization rate had recovered to the levels before CPA administration.
One reason for ovarian function failure was the depletion of the primordial follicle stockpile following treatment with the cytotoxic agent, CPA. The reactivity of the ovaries depends on the dose; the more the dose, the lower is the ovarian reserve. 13 A past animal and human study suggested the presence of the direct toxic effect of chemotherapy on follicles 17 and large apoptosis in the growing phase of CPA-administered mice follicles, but not in the resting follicles. 18 Moreover, injury to the entire ovary that resulted in blood vessel occlusion, focal cortical fibrosis, and the disappearance of the primordial follicle from fibrotic zones 19 also have been observed.
When patients who were treated with chemotherapy or surgery desired to maintain their fecundity after treatment, some time was required for the recovery of their ovarian function. Ovarian stimulation in IVF protocols usually altered the ovarian physiology, considering that the ovarian volume and blood flow dramatically increase on stimulation. 20 Therefore, it was hypothesized that overstimulation F I G U R E 1 Study design regarding the dose, which was 0, 50, 100, 200, or 400 mg/kg per day. The dose of 800 mg/kg was administered over 2 days (400 mg/kg per day for 2 days). The control group was injected with saline only. CPA, cyclophosphamide; hCG, human chorionic gonadotropin; IVF, in vitro fertilization; PMSG, pregnant mare's serum gonadotropin prior to chemotherapy can reduce ovarian damage. It also has been hypothesized that the ovarian reserve might decline as more anticancer drugs increase follicular destruction. One study reported that ovarian stimulation before CPA administration did not adversely affect the ovarian reserve after treatment. 15 Another hypothesis sug- the oocyte fertilization ability and embryo growth in mice. Further studies are required to evaluate the effect of CPA on oocytes by evaluating the pregnancy rate, the number of fetuses, and the degree of growth by using embryos that are collected after CPA administration. Moreover, the effect of CPA on the mitochondrial function, DNA damage, and epigenetic change remain unknown.
In the future, ovarian histological evaluation of the follicular development status would enable the investigation of the influence of CPA administration on the ovary.
As the survival rate of young patients who are receiving cancer treatment is increasing, it has become important to improve the quality of life of cancer survivors. The preservation of fertility is an indispensable step across all treatment regimens in young patients with cancer; cancer treatment often induces a reduction in fertility. The most readily available method for fertility preservation is the cryopreservation of the embryo and ovarian tissues. [21] [22] [23] [24] [25] One option is to perform natural-cycle IVF. 26 However, in order to preserve future fertility, the ovaries are stimulated with folliclestimulating hormone or human menopausal gonadotropin to induce ovulation, after which multiple eggs are harvested, fertilized, and saved for future use. In most cases, chemotherapy is initiated shortly after fertility preservation. Therefore, it is important to attain more knowledge about oocyte efficiency in relation to chemotherapy.
In conclusion, the results of this study showed that ovarian stimulation immediately following CPA administration does not adversely affect the ovarian reserve despite a decrease in the number of oocytes after 2 weeks of CPA treatment, when the ovarian function recovers to the normal pre-CPA administration levels. These observations recommend conformance to safety in fertility preservation procedures (IVF-embryo cryopreservation or unfertilized oocyte cryopreservation) in patients with cancer who are undergoing ovarian stimulation.
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